sellWeak cluster of 4
Jane Henderson sold $142k of AKRO
director at Akero Therapeutics, Inc.. 3,000 shares at an average of $47.46, traded Aug 12, 2025, filed Aug 12, 2025.
Warning score
31Value
$142k
3,000 shares
Holdings after
9,398
-24% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleDirector
- +11Trade size$142k at market
- +5Share of holdings soldSold 24% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-107545, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 12, 2025 | MOption exercise Common Stock | +3,000 | $7.01 | $21k | 12,398 | Aug 12, 2025 |
| Aug 12, 2025 | SOpen-market sale Common Stock | -3,000 | $47.46 | $142k | 9,398 | Aug 12, 2025 |
| Aug 12, 2025 | MOption exercise Stock Option (Right to Buy)derivative | -3,000 | $0.00 | $0 | 11,797 | Aug 12, 2025 |
Related signals
Other insiders at Akero Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Akero Therapeutics, Inc. | Andrew Cheng President and CEO | $1.6M 30,000 shares | -5% | |
| 14Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $576k 12,500 shares | -7% | |
| 19Weak | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $597k 12,500 shares | -6% | |
| 30Weak | Akero Therapeutics, Inc. | Andrew Cheng President and CEO | $1.4M 31,796 shares | -6% | |
| 30Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $24k 553 shares | -0% | |
| 42Moderate | Akero Therapeutics, Inc. | William Richard White Chief Financial Officer | $28k 659 shares | -1% | |
| 35Weak | Akero Therapeutics, Inc. | Catriona Yale Chief Development Officer | $28k 659 shares | -1% | |
| 40Moderate | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $25k 586 shares | -0% | |
| 14Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $552k 12,500 shares | -7% | |
| 19Weak | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $576k 12,500 shares | -6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.